These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. Brocks DR; Meikle AW; Boike SC; Mazer NA; Zariffa N; Audet PR; Jorkasky DK J Clin Pharmacol; 1996 Aug; 36(8):732-9. PubMed ID: 8877678 [TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ J Androl; 1998; 19(6):761-8. PubMed ID: 9876028 [TBL] [Abstract][Full Text] [Related]
25. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women. Rohr UD; Ehrly AM; Kuhl H Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456 [TBL] [Abstract][Full Text] [Related]
26. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Dobs AS; Matsumoto AM; Wang C; Kipnes MS Curr Med Res Opin; 2004 May; 20(5):729-38. PubMed ID: 15140340 [TBL] [Abstract][Full Text] [Related]
27. Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. De Sanctis V; Vullo C; Urso L; Rigolin F; Cavallini A; Caramelli K; Daugherty C; Mazer N J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():891-900. PubMed ID: 10091163 [TBL] [Abstract][Full Text] [Related]
28. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men]. Asscheman H; Gooren LJ Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. Javanbakht M; Singh AB; Mazer NA; Beall G; Sinha-Hikim I; Shen R; Bhasin S J Clin Endocrinol Metab; 2000 Jul; 85(7):2395-401. PubMed ID: 10902784 [TBL] [Abstract][Full Text] [Related]
30. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. Rochira V; Balestrieri A; Madeo B; Granata AR; Carani C J Androl; 2006; 27(2):165-75. PubMed ID: 16278367 [TBL] [Abstract][Full Text] [Related]
31. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. Yu Z; Gupta SK; Hwang SS; Kipnes MS; Mooradian AD; Snyder PJ; Atkinson LE J Clin Pharmacol; 1997 Dec; 37(12):1139-45. PubMed ID: 9506009 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. Dobs AS; Hoover DR; Chen MC; Allen R J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413 [TBL] [Abstract][Full Text] [Related]
33. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. Wang C; Harnett M; Dobs AS; Swerdloff RS J Androl; 2010; 31(5):457-65. PubMed ID: 20133964 [TBL] [Abstract][Full Text] [Related]
35. Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. Mazer N; Fisher D; Fischer J; Cosgrove M; Bell D; Eilers B J Sex Med; 2005 Mar; 2(2):227-34. PubMed ID: 16422890 [TBL] [Abstract][Full Text] [Related]
36. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index. Dobs A; Norwood P; Potts S; Gould E; Chitra S J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410 [TBL] [Abstract][Full Text] [Related]
37. Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. Yu Z; Gupta SK; Hwang SS; Cook DM; Duckett MJ; Atkinson LE J Clin Pharmacol; 1997 Dec; 37(12):1129-38. PubMed ID: 9506008 [TBL] [Abstract][Full Text] [Related]
38. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
39. Testosterone supplementation: what and how to give. Jockenhövel F Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500 [TBL] [Abstract][Full Text] [Related]
40. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Behre HM; von Eckardstein S; Kliesch S; Nieschlag E Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]